All stocks / BLGO
BIOLARGO, INC. BLGO
Biolargo (BLGO): no warning signs from our rules in the last 12 months and the latest annual figures in plain language. Each fact links to its SEC filing.
Market listing
- Full name
- BIOLARGO INC
- Market tier
- OTCQX US
- Trading status
- Active
- Last trade
- Nov 16
- Website
- www.biolargo.com/
News headlines
The financial report, and what it means
Annual figures to 2025-12-31- Net loss
- ($15,189,000)
It spends more than it earns
Under strainThe company lost $15.2 million in the year. It reported no sales.
- Cash and cash equivalents
- $3,883,000
- Net cash used in operating activities
- ($8,297,000)
The cash could run out soon
Under strainIt had $3.9 million in the bank and used about $691,417 a month. At that pace the money lasts about 6 months unless it borrows or sells more shares.
- Total assets
- $8,311,000
- Total liabilities
- $6,785,000
It owns more than it owes
SteadyEverything the company owns adds up to $8.3 million. Its debts and unpaid bills add up to $6.8 million. That is about $0.82 owed for every $1 owned.
What this adds up to
2 of 3 checks show strain. It spends more than it earns. The cash could run out soon. These are facts from the company's own reports, not a recommendation.
Signals
Estimated float about 299,479,232 shares as of 2026-11-12: 338,443,806 outstanding minus 38,964,574 held by 2 reporting insider(s).
Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record
Shares outstanding
Source: SEC filingsPrice chart
Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets
Recent filings
Common questions about BLGO
Does BLGO file reports with the SEC?
Yes. Biolargo files with the SEC under company number 0000880242. The most recent filing we hold is a 10-Q dated 2026-11-16.
Source recordHow many BLGO shares are outstanding?
338,443,806 shares as of 2026-11-12, as reported to the SEC.
Source recordHas BLGO filed reports late?
We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.
Who runs Biolargo?
Officers named in its insider filings: Dennis P Calvert (President), Kenneth Reay Code (Chief Science Officer) and Charles K Dargan (Chief Financial Officer).
Source recordIs Biolargo making money?
The company lost $15.2 million in the year. It reported no sales. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)
Source record